<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666962</url>
  </required_header>
  <id_info>
    <org_study_id>2018[136]</org_study_id>
    <nct_id>NCT03666962</nct_id>
  </id_info>
  <brief_title>Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation</brief_title>
  <official_title>Evaluating Medication Adherence to Novel Oral Anticoagulants With Anticoagulant Activity Monitoring in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cui Yimin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The novel oral anticoagulants such as rivaroxaban, apixaban and dabigatran, specifically
      target either thrombin or factor Xa/IIa. These new agents are included as an option for
      prevention of thromboembolic disease or recurrent stroke in patients with non-valvular atrial
      fibrillation in guidelines.

      Although the benefits and risks of anticoagulation and antiplatelet therapy have been fully
      assessed, and reasonable anticoagulation and antiplatelet therapies have been formulated, the
      therapeutic effect still largely depends on the quality control during the treatment. Many
      patients discontinue anticoagulant therapy after discharge or after a period of treatment,
      and the risk of thrombosis increases. Because non-vitamin K antagonist oral anticoagulants
      (NOACs) does not need routine monitoring, patients tend to ignore the regular medication,
      thus affecting drug compliance. Because of the short half-life of NOACs, if patients do not
      take it regularly, not only can not achieve the effectiveness of anticoagulation, but also
      reduce the safety of medication. More and more researchers have realized that medication
      adherence plays a key role in medical management. In order to improve the efficacy and safety
      of NOACs and the compliance of patients with NOACs, the guidelines emphasize that
      supplementary measures can be taken, such as pharmacists participating in the network
      pharmacy database, attaching importance to the medication education of patients and their
      families, formulating a strict follow-up plan and professional outpatient follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with new oral anticoagulants will be included in the study. After the signing of the
      informed consent, blood samples were collected to detect the anti Xa factor activity after
      taking the drugs. Meanwhile, the medication compliance of the patients during the treatment
      was also collected.

      Dedicated tests based on anti-Xa activity for rivaroxaban and apixaban and anti-IIa activity
      for dabigatran concentration was conducted. Blood samples are divided into peak concentration
      and valley concentration. Peak concentration (Cmax) refers to the highest serum concentration
      after administration for at least one week in the study. Valley concentration (Cmin), the
      lowest concentration during administration, is usually obtained from the lowest concentration
      between the initial time of administration and the next time the drug is administered at a
      steady state (continuous medication for more than 1 weeks.).

      A compliance questionnaire was conducted to collect the compliance of the drug during
      treatment. The Morisky, Green, and Levine Adherence Scale (MGLS) was used to evaluate the
      medication adherence of non-vitamin K antagonist oral anticoagulants (NOACs) patients.

      Based on the results of data analysis, the correlation between anti Xa/IIa activity test
      results and medication compliance was analyzed, making the anti Xa/IIa activity concentration
      a simple measure to predict the compliance of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic indicators</measure>
    <time_frame>at least 1 week after drug administration</time_frame>
    <description>Blood samples are divided into peak concentration and valley concentration. Peak concentration (Cmax) refers to the highest serum concentration after administration for at least one week in the study. Valley concentration (Cmin), the lowest concentration during administration, is usually obtained from the lowest concentration between the initial time of administration and the next time the drug is administered at a steady state (continuous medication for more than 1 weeks.).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication adherence</measure>
    <time_frame>at least 1 week after drug administration</time_frame>
    <description>A compliance questionnaire was conducted to collect the compliance of the drug during treatment. According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anticoagulants</condition>
  <condition>Compliance, Medication</condition>
  <arm_group>
    <arm_group_label>case group</arm_group_label>
    <description>According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples are divided into peak concentration and valley concentration. Peak
      concentration (Cmax) refers to the highest serum concentration after administration for at
      least one week in the study. Valley concentration (Cmin), the lowest concentration during
      administration, is usually obtained from the lowest concentration between the initial time of
      administration and the next time the drug is administered at a steady state (continuous
      medication for more than 1 weeks.).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who take NOACs at Peking University First Hospital
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. confirmed diagnosis of NOACs indications, such as thromboprophylaxis for non-valvular
             atrial fibrillation, prevention or treatment of deep vein thrombosis/pulmonary
             embolism, and thromboprophylaxis after knee/hip replacement.

          2. Age &gt;18 years old, unlimited for gender.

          3. Written or phoned informed consent was obtained from all patients or their families.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qian Xiang, Ph.D</last_name>
    <phone>+86 010 66110802</phone>
    <email>xiangqz@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Na Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 7th People's hospital of the zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongdong Yuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian Xiang, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yatong Zhang</last_name>
      <email>zyt2002888@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhua Zhang</last_name>
      <email>pollyzhang2006@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou General Hospital of Nanjing Militray Command</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taotao Hu</last_name>
      <email>412456139@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital#The First Affiliated Hospital Of USTC#</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaoyi Yang</last_name>
      <email>young2382@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Cui Yimin</investigator_full_name>
    <investigator_title>Director of pharmacyï¼ŒM.D &amp; Ph.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

